{"id":"NCT00262522","sponsor":"Abbott","briefTitle":"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","officialTitle":"A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2005-12-07","resultsPosted":"2009-08-20","lastUpdate":"2012-02-06"},"enrollment":664,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Infections"],"interventions":[{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]},{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)","otherNames":["ABT-378, Kaletra, lopinavir/ritonavir"]}],"arms":[{"label":"LPV/r 800/200 mg QD Tablet","type":"EXPERIMENTAL"},{"label":"LPV/r 800/200 mg QD SGC (Through Week 8)","type":"EXPERIMENTAL"},{"label":"LPV/r 400/100 mg BID Tablet","type":"ACTIVE_COMPARATOR"},{"label":"LPV/r 400/100 mg BID SGC (Through Week 8)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to compare the safety and tolerability of the to-be-marketed lopinavir/ritonavir (LPV/r) tablet formulation with the marketed soft gel capsule (SGC) formulation and to compare the safety, tolerability, and antiviral activity of once daily (QD) and twice daily (BID) dosing of the LPV/r tablet formulation in combination with select nucleoside reverse transcriptase inhibitors (NRTIs) in patients who have not previously received antiretroviral treatment.","primaryOutcome":{"measure":"Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks","timeFrame":"Week 8","effectByArm":[{"arm":"LPV/r 800/200 mg QD Tablet","deltaMin":49.1,"sd":null},{"arm":"LPV/r 800/200 mg QD SGC (Through Week 8)","deltaMin":54.8,"sd":null},{"arm":"LPV/r 400/100 mg BID Tablet","deltaMin":44.6,"sd":null},{"arm":"LPV/r 400/100 mg BID SGC (Through Week 8)","deltaMin":49.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002 vs OG003","p":">0.100"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":129,"countries":["United States","Australia","Belgium","Canada","Czechia","France","Germany","Greece","Ireland","Italy","Netherlands","Poland","Puerto Rico","Russia","Singapore","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":333},"commonTop":["Diarrhea","Nausea","Nasopharyngitis","Vomiting","Fatigue"]}}